Bangor Savings Bank increased its position in Amgen Inc. (NASDAQ:AMGN) by 2.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,500 shares of the medical research company’s stock after buying an additional 59 shares during the period. Bangor Savings Bank’s holdings in Amgen were worth $410,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Camelot Portfolios LLC bought a new stake in Amgen during the first quarter valued at about $1,429,000. Private Asset Management Inc. increased its position in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock worth $589,000 after buying an additional 1,942 shares during the last quarter. Cadence Bank NA increased its position in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after buying an additional 197 shares during the last quarter. Stillwater Capital Advisors LLC purchased a new position in shares of Amgen during the first quarter valued at about $202,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Amgen during the fourth quarter valued at about $275,209,000. Institutional investors own 79.53% of the company’s stock.
Amgen Inc. (NASDAQ AMGN) opened at 173.55 on Thursday. The company has a 50-day moving average of $174.67 and a 200-day moving average of $167.36. The company has a market cap of $126.63 billion, a price-to-earnings ratio of 15.81 and a beta of 1.35. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the business posted $2.84 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. Equities research analysts expect that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.65%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.
ILLEGAL ACTIVITY NOTICE: “Bangor Savings Bank Has $410,000 Stake in Amgen Inc. (AMGN)” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/08/10/amgen-inc-amgn-shares-bought-by-bangor-savings-bank-updated.html.
Several research firms have weighed in on AMGN. UBS AG restated a “neutral” rating and issued a $174.00 price objective (down previously from $175.00) on shares of Amgen in a research report on Monday, May 22nd. Mizuho set a $195.00 price target on shares of Amgen and gave the stock a “buy” rating in a research report on Saturday, May 6th. BMO Capital Markets restated a “buy” rating and set a $198.00 price objective (down previously from $200.00) on shares of Amgen in a report on Monday, May 22nd. Cowen and Company restated an “outperform” rating and set a $209.00 price objective on shares of Amgen in a report on Wednesday, April 19th. Finally, Morgan Stanley boosted their price objective on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.